Oligonucleotide Proximity Ligation for Protein Aggregate Detection
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for detecting protein aggregates, such as prions, face challenges including poor sensitivity, high false positives, limited applicability, and high costs due to the ubiquitous expression of prion proteins and their poor solubility, making reliable biochemical-based diagnostic tests for neurodegenerative diseases like Alzheimer's, Huntington's, and Parkinson's difficult to develop.
Innovation Solution
The use of proximity ligation assay (PLA) with oligonucleotide-labeled precursor molecules that self-assemble into protein aggregates, allowing for the detection of these aggregates through PCR amplification without the need for antibodies, thereby improving sensitivity and reducing false positives.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If antibody-based methods are used to detect protein aggregates, then detection can be performed, but sensitivity is poor and false positives are high
Solution Approach 1:
The patent introduces oligonucleotide labels as intermediary molecules that bind to protein aggregates through hybridization. These oligonucleotide-protein conjugates serve as intermediaries that can be specifically detected by PCR, replacing direct antibody detection and thereby improving sensitivity and reducing false positives.
Solution Approach 2:
The patent replaces the antibody-antigen recognition system with an oligonucleotide hybridization system. This substitution allows for more specific and sensitive detection because oligonucleotide hybridization can be designed with higher specificity and detected through amplification methods like PCR.
2Adaptability or versatility
If prion protein detection methods are developed, then diagnostic capability is improved, but costs are high due to ubiquitous expression and poor solubility
Solution Approach 1:
The patent employs the self-assembly property of misfolded prion proteins to automatically concentrate and label themselves with oligonucleotides. This self-service mechanism eliminates the need for complex purification and labeling procedures, reducing costs while maintaining diagnostic versatility across different prion diseases.
3Measurement precision
If oligonucleotide-labeled precursor molecules are used, then detection sensitivity is improved, but the complexity of the assay increases
Solution Approach 1:
The patent merges the detection of protein aggregates with oligonucleotide hybridization and PCR amplification into a single integrated assay. By combining these functions, the overall complexity is managed through a unified protocol that leverages the strengths of each component while improving sensitivity.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach enables efficient and cost-effective detection of protein aggregates, including prions, in biological samples, providing a reliable method for diagnosing neurodegenerative diseases by leveraging the self-assembly properties of misfolded proteins.
Implementation Method 1
The use of proximity ligation assay (PLA) with oligonucleotide-labeled precursor molecules that self-assemble into protein aggregates
Implementation Method 2
interacting the first oligonucleotide of the first precursor molecule with the second oligonucleotide of the second precursor molecule, to form an interaction composition
Implementation Method 3
allowing for the detection of these aggregates through PCR amplification
Data Source
AI summary
The present teachings provide methods, compositions, and kits for detecting the presence of protein aggregates. In some embodiments, the protein aggregate is treated with a labeled precursor, and the labeled precursor is incorporated into the protein aggregate to form a labeled protein aggregate. The labeled protein aggregate is then measured, thus detecting the presence of the protein aggregate. In some embodiments, the labeled protein aggregate is detected by interaction of labeled precursors, for example by a proximity ligation assay.